Head of Biologic Business Development at SK Bioscience, responsible for building biologic business strategy to enable next phase of growth for the company, leading M&A, J/V, partnerships, licensing, and ultimately management and operation of companies and assets. Before SK Bioscience, Kenneth served as the Head of Commercial Division, Americas, at GenScript ProBio, providing biologics & GCT discovery, development, and manufacturing solutions to clients across America. Kenneth was in charge of establishing and growing GenScript ProBio’s commercial organization, leading 7x sales growth within 4 years he was there. Prior to GenScript ProBio, Kenneth led global launches and commercialization of Samsung Bioepis’ world-leading biosimilar pipelines, playing a key role in rapidly bringing them to $1B sales globally within 4 years of the first product launch, while successfully overseeing Samsung Bioepis’ global commercial partnerships with Merck and Biogen. Before joining Samsung Bioepis, Kenneth led business development team at Binex, closing global CDMO, licensing, and tech-transfer deals with #1 pharmas by sales in Russia and Turkey, and #1 generic company by sales in Japan. In earlier stages of his career, Kenneth worked in medicinal chemistry, bioanalytical testing, and quality assurance functions at global biopharmaceutical companies including Gilead Sciences and BioMarin Pharmaceuticals. Kenneth has B.S. in Molecular Cell Biology from University of California, Berkeley, with concentration on Genetics and Cells and Development Biology, and MBA from INSEAD/ Wharton. Outside of work, Kenneth is an active supporter of World Vision and other charitable causes, and a recognized performing musician as well as a Praise & Worship leader within churches.